New Market - June 1, 2015
Isofol Drug Receives US Patent
The use and pharmaceutical composition of Isofol Medical AB’s [6R]-methylene-tetrahydrofolate (Modufolin®), to reduce toxicity resulting from multi-targeting antifolate chemotherapy, has received a patent from the U.S. Patent and Trademark Office. Modufolin® is a folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. Isofol provided evidence demonstrating the […]